TRI Thrombosis Research Institute

VTE Garfield
global anticoagulant registry in the field

Monthly Status Report

January, 2018

The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG

Project Timeline- Overview

- 01-JUL-14 Recruitment Start (FPFV)
- JAN 2016 LPFV (COHORT 1), First draft of methods paper
- AUG 2016 12th August 2016, 10127 patients recruited
- SEP 2016 Recruitment end
- OCT 16 Phase I On-Site Monitoring Start
- 31-DEC-201 Brazil and US stopped recruiting. GARFIELD – VTE recruitment is officially closed.
- April 17 Phase I On-Site Monitoring Completed
- Feb 2017 eCRF Update
- April 2017 6 Months 10,000+ and 12Months 5000 patients data cleaned and completed
- Oct 2017 Ambassadors' Meeting

OCT 17

- Ambassadors' meeting
- Deadline for manual query raised
- Phase II SDV
- SA IM

Nov 17

- Australia IM
- Payment data cut

Dec 17

- Site Payment
- Manual Query data cleaning deadline

Jan 18

Apr - 10,000+ 12 Months Data Cut
Phase II SDV

2019

LPLV – Quintiles Countries

The GARFIELD-VTE registry is funded by an unrestricted research grant from Bayer AG

Recruitment Status

Total Recruitment	10,873
Number of Sites selected	477
Number of sites with EC approval/Regulatory approval	441
No of fully executed contracts	442
SIVs completed	442



The GARFIELD-VTE registry is funded by an unrestricted research grant from Bayer AG

Global- Patients Milestone Status

Jan 8th, 2018

The GARFIELD-VTE registry is funded by an unrestricted research grant from Bayer AG

Queries Completion

Jan 8th, 2018



The GARFIELD-VTE registry is funded by an unrestricted research grant from Bayer AG

Questionnaires

Jan 8th, 2018





The GARFIELD-VTE registry is funded by an unrestricted research grant from Bayer AG

GARFIELD-VTE Publication Plan



*Submission and publication timelines are provisional and subject to change

The GARFIELD-VTE registry is funded by an unrestricted research grant from Bayer AG